Form 4: PTC Therapeutics Exec Sells Shares, Exercises Options
Insider Transaction Report
Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, reported multiple stock transactions, including option exercises and sales, primarily for tax withholding and under a 10b5-1 plan.
Summary
- Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT), reported several transactions involving the company's common stock and stock options.
- On January 6, 2026, 1,739 shares of common stock were sold at $76.95 per share to satisfy tax withholding obligations related to the vesting of 4,500 Restricted Stock Units (RSUs) from a January 3, 2025 grant.
- On January 7, 2026, 1,503 shares of common stock were sold at $77.48 per share to satisfy tax withholding obligations related to the vesting of 4,250 RSUs from a January 5, 2023 grant.
- Also on January 7, 2026, Boulding exercised stock options to acquire 2,625 shares of common stock at an exercise price of $38.1 per share.
- Following this exercise, 1,638 shares were sold at a weighted average price of $77.11, 949 shares at $77.91, 38 shares at $78.6, 471 shares at $77.1, 269 shares at $77.92, and 11 shares at $78.98.
- Another 751 stock options were exercised on January 7, 2026, at $38.1 per share, resulting in the acquisition of 751 shares of common stock.
- Many of these transactions were executed pursuant to a Rule 10b5-1 plan adopted by Boulding on December 4, 2024.
- Following all reported transactions, Boulding's direct beneficial ownership of common stock was 117,659 shares.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions, including option exercises and sales, some for tax purposes and others under a pre-arranged 10b5-1 plan. While there is net selling, the pre-planned nature and tax-related sales mitigate strong negative sentiment. The transactions are largely neutral in terms of company-specific news, reflecting personal financial management rather than a direct statement on company prospects.
Positives
- The executive exercised stock options at a strike price of $38.1, significantly below the market sale prices ranging from $76.54 to $78.98, indicating a profitable transaction for the individual.
- The use of a Rule 10b5-1 plan demonstrates pre-planned transactions, which can reduce concerns about opportunistic insider trading.
Negatives
- The executive engaged in net selling of common stock, reducing their direct beneficial ownership from 119,162 shares (before the first reported sale) to 117,659 shares after all transactions.
- A significant portion of the sales were 'sell to cover' transactions to satisfy tax withholding obligations, which, while common, still represent a reduction in direct equity holdings.
Risks
- While not explicitly stated as a risk, a pattern of executive selling, even for tax purposes or under a 10b5-1 plan, could be interpreted by some investors as a lack of confidence in the company's near-term stock performance.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports on insider transactions.
Industry Context
This filing, a standard insider transaction report, does not provide information to analyze how these specific transactions relate to broader industry trends or competitors within the biotechnology or pharmaceutical sector. It reflects individual executive compensation and personal financial planning.
Stakeholder Impact
- Shareholders: The net selling by a key executive, even if pre-planned and for tax purposes, could be viewed with slight caution by some shareholders, though the overall volume is not exceptionally large relative to the company's market capitalization.
- Employees: No direct impact on employees is indicated by this filing.
- Customers: No direct impact on customers is indicated by this filing.
- Suppliers: No direct impact on suppliers is indicated by this filing.
- Creditors: No direct impact on creditors is indicated by this filing.
Next Steps
- The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the execution of the pre-arranged 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 2023-01-05 | Grant date of 17,000 RSUs, from which 4,250 RSUs vested, leading to a sell-to-cover transaction. |
| 2024-12-04 | Date the Reporting Person adopted the Rule 10b5-1 plan for future transactions. |
| 2025-01-03 | Grant date of 18,000 RSUs, from which 4,500 RSUs vested, leading to a sell-to-cover transaction. |
| 2026-01-06 | Date of earliest reported transaction: sale of 1,739 shares for tax withholding. |
| 2026-01-07 | Date of multiple transactions including RSU-related sales, option exercises, and subsequent stock sales. |
| 2026-01-08 | Date the Form 4 was signed by the Attorney-in-Fact. |
| 2032-01-06 | Expiration date for the exercised stock options. |
Keywords
PTC Therapeutics, PTCT, Insider Trading, Form 4, Stock Options, RSU Vesting, Executive Compensation, Mark Elliott Boulding, Rule 10b5-1 Plan, Equity Sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.